

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Amended) ~~Use of A method of treating cancer comprising administering an~~
adenovirus defective in its VAI and VAII virus-associated RNAs ~~for the production of a~~
~~pharmaceutical composition for the treatment of cancer.~~
2. (Amended) Use The method according to Claim 1, wherein said adenovirus has a
mutation in the sequences of the VAI and VAII RNA genes.
3. (Amended) Use The method according to Claim 1, wherein said adenovirus has a
mutation in the sequences of the genes that control the expression of the VAI and VAII RNA
genes.
4. (Amended) Use The method according to ~~any one of the preceding claims~~ Claim
1, wherein said adenovirus has mutations in the VA RNA genes in one or more genes of the
group E1a, E1b, and E4 to obtain selective replication in tumors.
5. (Amended) Use The method according to ~~any one of the preceding claims~~ Claim
1, wherein said adenovirus has mutations in the VA RNA genes and promoters that regulate one
or more genes in the group E1a, E1b, and E4 to obtain selective replication in tumors.

6. (Amended) Use The method according to ~~any one of the preceding claims~~ Claim 1, wherein said adenovirus has mutations in the VA RNA genes to obtain selective replication in tumor cells with an active Ras pathway or unresponsive to the action of interferon.

7. (Amended) Use The method according to ~~any one of the preceding claims~~ Claim 1, wherein said adenovirus has mutations in the VA RNA genes to obtain selective replication in tumor cells and modifications in its capsid to increase its infectivity or to direct it to a receptor present on a tumor cell.

8. (Amended) Use The method according to ~~any one of the preceding claims~~ Claim 1, wherein said adenovirus has mutations in the VA RNA genes that confer selective replication on tumor cells and that, in turn, contain other genes commonly used in the field of cancer gene therapy such as prodrug activators, tumor suppressors, or immunostimulants.

9. (Amended) Use The method according to ~~any one of the preceding claims~~ Claim 1, wherein said adenovirus is a human adenovirus derived from a serotype between 1 and 50 with genetic mutations in the VA RNAs genes that confer selective replication on tumor cells.

10. (Amended) Use The method according to Claim ~~11~~ 9, wherein said adenovirus is a human adenovirus derived from serotype 5.

11. (Amended) Use The method according to ~~Claims 11 to 12~~ Claim 9, wherein said adenovirus is a mutant adenovirus dl331.